We caught up with our Chief Science Officer here at AxisBiotix, Dr Catherine O’Neill, to find out more about what has inspired her to not only become a world-renowned professor, but also a successful entrepreneur.
Dr Catherine O’Neill is no stranger to the demanding nature of running a business. With a passion for horses and dogs, her day starts early as she tends to their needs before breakfast. Her morning routine includes a hearty breakfast of porridge with banana, which provides her with the energy she needs to power through the day.
Dr Cath’s mantra for a working day is to “shut up and get on with it,” which she finds helps her overcome any challenges that come her way. As a business leader, she acknowledges that it can be difficult to separate personal and business life, but she credits her pets as therapeutic for helping her switch off from work. So, if you’re looking for an excuse to purchase a puppy, there it is!).
For aspiring female entrepreneurs, Dr Cath advises being honest with yourself about what you want from your career and life, and having the confidence to back yourself. She doesn’t have a specific business idol, but admires those from all walks of life who make the most of their opportunities.
Dr O’Neill’s motivation comes from fear of not living life to the fullest. She believes that pushing through challenges and tackling them head on is the best approach. One of the biggest challenges she has faced in business is raising money, and she recognises that women-led firms in the UK struggle to attract equal investment. However, she remains hopeful about the future of female entrepreneurship in the UK, noting that the number of patents with female inventors has increased significantly in recent years.
With her passion for entrepreneurship and drive to make a difference in the world, Dr Cath continues to inspire others to pursue their dreams and overcome any obstacles that come her way.
About Dr Catherine O’Neill’s Research and Career
Dr Catherine O'Neill is a highly esteemed academic and scientist in the field of dermatology. She currently holds the position of Professor of Translational Dermatology at the University of Manchester, where she is a leading authority on skin diseases and their treatment. Dr O'Cath's work is highly interdisciplinary, combining expertise in dermatology, immunology, and molecular biology to develop innovative solutions for treating skin conditions.
Dr Cath is also the Chief Science Officer here at AxisBiotix and her work here has been pivotal in harnessing the power of the microbiome to help those living with skin conditions..
Dr Cath’s expertise in dermatology and microbiome research has led to numerous scientific breakthroughs and publications in top-tier academic journals. She is also a sought-after speaker and consultant, providing expert advice to governments, organisations, and companies on issues related to skin health and microbiome-based therapies.
Throughout her career, Dr Cath has received numerous awards and accolades for her contributions to the field of dermatology and scientific research. She is highly respected by her colleagues and peers, and her work is widely recognised as being at the forefront of translational research in dermatology.
To find out more about Dr Cath’s research, head to the link below:
https://www.researchgate.net/profile/Catherine-Oneill
We’ll soon be launching our #AskCath series, where Cath will answer your most asked questions. If you’ve got a question for Cath, please drop us an email at XX with your query and we will pose it to Cath to answer as part of our new video series launching across our social media channels very soon.
2 comments
The Boots Future Renew Serum is based on peptide technology rather than lysated probiotics. As such it poses zero threat to our technology, Boots have not stolen a march in the field. Thank you for your continued support.
Is the newly launching Future Renew Serum by Boots the same, or a similar formula to that which SBTX has provided to Croda/Sederma? Does the Boots formula incorporate Lysates? As significant shareholders in SBTX, we are concerned about the implications, as it appears that Boots could have stolen a march in this field.